Endosense Closes $40.3M Series C

Endosense, a developer of technology for catheter ablation for the treatment of cardiac arrhythmias, has raised $40.3 million in Series C financing. new investor NGN Capital led the round, which included investment from existing investors Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. Endosense was formed in Geneva in 2003.

North AmericaUSBriefs